Data source	Date of update	Product name	Alternative name	Product type	Non-traditionals categories	Antibacterial class	Indications	Route of administration	R&D phase	Clinical trials	Developer	Pathogen category	Pathogen name	Pathogen activity	Active against priority pathogens?	Innovative?	NCE?	Mycobacterium tuberculosis	Clostridioides difficile
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"Bacteriophage"		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	9MW1411	-	Non-traditional	Antibodies	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AB103	Reltecimod	Non-traditional	Immunomodulating agents	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Enterobacterales	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Afabicin	Debio 1450	Antibiotics	NA	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ALS-4	-	Non-traditional	Miscellaneous	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AP-PA02	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-301	Tosatoxumab	Non-traditional	Antibodies	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	AR-302	MEDI-4893, Suvratoxumab	Non-traditional	Antibodies	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ARX-1796	Oral Avibactam prodrug	Antibiotics	NA	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Benapenem	-	Antibiotics	NA	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BWC0977		Antibiotics	NA	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	BX004-A	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CAL02	-	Non-traditional	Miscellaneous	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	CF-301	Exebacase	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Delpazolid	LCB01-0371	Antibiotics	NA	Oxazolidinone	Pulmonary tuberculosis, Gram-positive bacterial infections	Oral	Phase II	NCT02836483, NCT04550832	LegoChem Biosciences Inc., HaiHe Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Durlobactam + sulbactam	ETX2514	Antibiotics	NA	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	EBL-1003	Apramycin	Antibiotics	NA	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Enmetazobactam + cefepime	AAl101 + cefepime	Antibiotics	NA	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	ETX0282 + cefpodoxime	–	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Ftortiazinon + cefepime	Fluorothyazinone	Non-traditional	Miscellaneous	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Gepotidacin	GSK2140944	Antibiotics	NA	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	GSK3882347	-	Non-traditional	Miscellaneous	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	KBP-7072	–	Antibiotics	NA	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LBP-EC01	–	Non-traditional	Bacteriophages and phage-derived enzymes	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LMN-101	–	Non-traditional	Antibodies	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	LSVT-1701	Tonabacase, SAL200	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	MRX-8	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nacubactam + meropenem	OP0595	Antibiotics	NA	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Nafithromycin	WCK 4873	Antibiotics	NA	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	OligoG	CF-5/20	Non-traditional	Miscellaneous	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Phage		Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2014	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX7728 + QPX2015	-	Antibiotics	NA	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	QPX9003	-	Antibiotics	NA	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	RG6006	Abx MCP	Antibiotics	NA	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Rhu-pGSN	Rhu-plasma gelsolin	Non-traditional	Immunomodulating agents	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Solithromycin	T-4288	Antibiotics	NA	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SPR-206		Antibiotics	NA	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Sulopenem, sulopenem etzadroxil/probenecid	PF-03709270	Antibiotics	NA	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Helicobacter pylori	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	SVT-1C469	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Taniborbactam + cefepime	VNRX-5133 + cefepime	Antibiotics	NA	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Possibly	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	Possibly	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	Possibly	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Possibly	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	Possibly	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2092	–	Antibiotics	NA	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	NA	?
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TNP-2198	-	Antibiotics	NA	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	Possibly	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	Possibly	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TRL1068	-	Non-traditional	Antibodies	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	TXA709	-	Antibiotics	NA	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	VNRX-7145 + ceftibuten	–	Antibiotics	NA	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	"XNW4107 +imipenem 
+ cilastin"	-	Antibiotics	NA	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Enterobacterales	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	All critical priority pathogens	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	YPT-01	-	Non-traditional	Bacteriophages and phage-derived enzymes	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	N/A	N/A	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Other priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Helicobacter pylori	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Enterococcus faecium	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Campylobacter spp.	Other priority pathogens	N/A	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zidebactam + cefepime	–	Antibiotics	NA	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Enterobacterales	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	Zoliflodacin	–	Antibiotics	NA	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	Yes	Yes	NA	NA
WHO AMR pipeline analysis	Nov-21	 GSK3036656	GSK070	Antibiotics	NA	Leu RS inhibitor (oxaborole)	Pulmonary tuberculosis	Oral	Phase II	NCT03557281	GlaxoSmithKline PLC	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	Yes	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	BTZ-043	-	Antibiotics	NA	DprE1 inhibitor (benzothiazinone)	Tuberculosis	Oral	Phase II	NCT03590600, NCT04044001	University of Munich; Hans Knöll Institute, Jena; German Center for Infection Research	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	Yes	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	BVL-GSK098	-	Non-traditional	Miscellaneous	Amido piperidine (inactivation of TetR-like repressor, EthR2)	Tuberculosis	Oral	Phase I	NCT04654143	Bioversys/ GSK	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	N/A	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	Delpazolid	LCB01-0371	Antibiotics	NA	Oxazolidinone	Pulmonary tuberculosis, Gram-positive bacterial infections	Oral	Phase II	NCT02836483, NCT04550832	LegoChem Biosciences Inc., HaiHe Biopharma	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	No	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	GSK2556286	GSK286	Antibiotics	NA	Undisclosed	Tuberculosis	Oral	Phase I	NCT04472897	GSK. TB Drug Accelarator/ Bill & Melinda Gates Foundation	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	Yes	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	Macozinone	PBTZ-169	Antibiotics	NA	DprE1 inhibitor (Benzothiazinone)	Pulmonary tuberculosis	Oral	Phase I	NCT03036163, NCT03776500, NCT03334734	Innovative Medicines for Tuberculosis Foundation and Nearmedic Plus	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	Yes	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	OPC-167832	–	Antibiotics	NA	DprE1 inhibitor (3,4-dihydrocarbostyril)	Pulmonary tuberculosis	Oral	Phase II	NCT03678688	Otsuka Pharmaceutical Co., Ltd.	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	Yes	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	Sutezolid	PNU-100480	Antibiotics	NA	Oxazolidinone	Pulmonary tuberculosis, Gram-positive bacterial infections	Oral	Phase II	NCT03959566	TB Alliance/ Sequella	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	No	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	TBA-7371	–	Antibiotics	NA	DprE1 inhibitor (azaindole)	Tuberculosis	Oral	Phase II	NCT04176250, NCT03199339	TB Alliance/ Bill & Melinda Gates Medical Research Institute/ Foundation for Neglected Disease Research	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	Yes	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	TBAJ-587	-	Antibiotics	NA	Diarylquinoline	Tuberculosis	Oral	Phase I	NCT04890535	TB Alliance	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	No	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	TBAJ-876	-	Antibiotics	NA	Diarylquinoline	Tuberculosis	Oral	Phase I	NCT04493671	TB Alliance	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	No	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	TBI-166	pyrifazimine	Antibiotics	NA	Riminophenazine (clofazimine-analogue)	Tuberculosis	Oral	Phase I	NCT04670120	Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	No	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	TBI-223	-	Antibiotics	NA	Oxazolidinone	Tuberculosis	Oral	Phase I	NCT03758612, NCT04865536	Institute of Materia Medica/ TB Alliance	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	No	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	Telacebec	Q203	Antibiotics	NA	Imidazopyridine amide	Pulmonary tuberculosis	Oral	Phase II	NCT03563599, NCT04847583	Qurient Co	Mycobacterium tuberculosis	Mycobacterium tuberculosis	N/A	N/A	Yes	Yes	y	NA
WHO AMR pipeline analysis	Nov-21	ART24	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	C. difficile infections	Oral	Phase I	NCT04891965	Artugen Therapeutics	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	BB128	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	Recurring C. difficile infections	Colonoscopy	Preregistration	-	BiomeBank	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	CP101	–	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase II	NCT03110133, NCT03497806	Finch Theraputics	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	CRS3123	REP 3123	Antibiotics	NA	 Diaryldiamine (Methionyl-tRNA synthetase inhibitor)	C. difficile infections	Oral	Phase II	NCT04781387	Crestone/ National Institute of Allergy and Infectious Diseases	Clostridioides difficile	Clostridioides difficile	N/A	N/A	Yes	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	DAV132	–	Non-traditional	Microbiome-modulating agents	Antibiotic inactivator and protective colon-targeted adsorbent	C. difficile infections	Oral	Phase II	NCT03710694	Da Volterra	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	DNV3837	MCB-3837	Antibiotics	NA	Oxazolidinone-quinolone hybrid	C. difficile infections	IV	Phase II	NCT03988855	Deinove	Clostridioides difficile	Clostridioides difficile	N/A	N/A	Inconclusive	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	Ibezapolstat	ACX-362E	Antibiotics	NA	Substituted guanine (DNA polymerae IIIIC inhibitor))	C. difficile infections	Oral, Not absorbed	Phase II	NCT04247542	Acurx Pharmaceuticals	Clostridioides difficile	Clostridioides difficile	N/A	N/A	Yes	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	IM-01	–	Non-traditional	Antibodies	anti-C. difficile polcyclonal Ab	C. difficile infections	Oral	Phase II	NCT04121169	ImmuniMed	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	LMN-201	-	Non-traditional	Bacteriophages and phage-derived enzymes	Phage endolysin and three toxin-binding proteins (5D, E3, and 7F)s	C. difficile infections	Oral	Phase I	NCT04893239	Lumen Bioscience	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	MET-2	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase I	NCT02865616, NCT04602715	NuBiyota/ Takeda	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	MGB-BP-3	–	Antibiotics	NA	DNA minor groove binder (distamycin)	C. difficile-associated diarrhea	Oral, Not absorbed	Phase II	NCT03824795	MGB Biopharma Ltd.	Clostridioides difficile	Clostridioides difficile	N/A	N/A	Yes	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	RBX2660		Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	C. difficile	Enema	Phase III	NCT03931941	Ferring Pharmaceuticals	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	RBX7455	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase I	NCT02981316	Ferring (Rebiotix)	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	Ridinilazole	SMT19969	Antibiotics	NA	Bis-benzimidazole	C. difficile infections	Oral, Not absorbed	Phase III	NCT02784002, NCT02092935, NCT03595553, NCT03595566, NCT04802837	Summit Therapeutics Inc.	Clostridioides difficile	Clostridioides difficile	N/A	N/A	Yes	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	SER-109	-	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	C. difficile infections	Oral	Phase III	NCT03183128, NCT03183141	Seres Theraputics	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	SYN-004	Ribaxamase	Non-traditional	Microbiome-modulating agents	Antibiotic inactivator	C. difficile infections	Oral	Phase II	NCT02563106, NCT04692181	Synthetic Biologics	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
WHO AMR pipeline analysis	Nov-21	VE303	–	Non-traditional	Microbiome-modulating agents	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase II	NCT03788434	Vedanta Biosciences	Clostridioides difficile	Clostridioides difficile	N/A	N/A	N/A	Yes	NA	y
